Background: During the course of acromegaly, cardiovascular, respiratory, and metabolic co-morbidities contribute to enhanced mortality. In 2002, the Pituitary Society and the European Neuroendocrine Association sponsored a Consensus Workshop in Versailles during which guidelines for diagnosis and treatment of co-morbidities in acromegaly were defined. However, as for other guidelines previously issued in the field, no data are available on their clinical application. Aim: The aim of this work coordinated by the Italian Study group on co-morbidities evaluation and treatment in acromegaly (COM.E.T.A.) was to assess, on a national basis, the application in the clinical practice of the Versailles criteria for diagnosis and treatment of cardiovascular comorbities in acromegaly. Materials and methods: In January 2007 an ad hoc designed questionnaire was sent by mail to 130 endocrine Centers in Italy. Results: The guidelines have been generally well perceived and translated in clinical practice. Specifically: 1) echocardiography is considered the mainstay for the diagnosis and follow-up; 2) ambulatory blood pressure monitoring and blood lipid assessment are performed in most hypertensive patients; 3) most endocrinologists directly manage hypertension and are aware of the uncertainty of the effect of the control of the disease on blood pressure levels; 4) ACE inhibitors and angiotensin receptors blockers are first-choice anti-hypertensive treatment; 5) approximately half of the centers consider somatostatin analogues of paramount relevance for biochemical control of disease; 6) awareness that left ventricular hypertrophy and heart failure are the most relevant cardiovascular complications is high although the impact of ischemic, arrhythmic, and valvular complications on prognosis is less well perceived. Conclusion: The results of the present survey suggest that previuosly issued guidelines are generally carefully followed in the clinical practice. On the other side, a certain lack of awareness of emerging aspects of the cardiovascular comorbities of acromegaly confirms the necessity of periodically updating the guidelines based on the availability of new clinical information. ©2008, Editrice Kurtis.
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) study / Giustina, A.; Mancini, T.; Boscani, P. F.; De Menis, E.; Degli Uberti, E.; Ghigo, E.; Martino, E.; Minuto, F.; Colao, A.; Comorbidities Evaluation, Com E. T. A.; Treatment Inacromegaly Italian Study Group, ; Aimaretti, G.; Ambrosio, M. R.; Andreani, M.; Angeletti, G.; Appetecchia, M. L.; Armigliato, M.; Arnaldi, G.; Arosio, M.; Babini, A.; Baldi, F.; Balza, G.; Barbaro, D.; Bartalena, L.; Battista, C.; Bechi, R.; Beck Peccoz, P.; Bellastella, A.; Bevilacqua, M.; Boccuzzi, G.; Boffano, G. M.; Bondanelli, M.; Borretta, G.; Boscaro, M.; Buschini, M.; Campanini, M.; Cannavo, S.; Carani, C.; Carpenito, F.; Carzaniga, C.; Castelli, A.; Cavagnini, F.; Chiarini, V.; Chiodera, P.; Colombo, M.; Colombo, P.; Coppola, A.; Cozzi, R.; Crivellaro, C.; D'Antonio, R.; Davi, M.; De Marinis, L.; De Matte, S.; De Remigis, P.; Del Monte, P.; Delitala, G.; Doveri, G.; D'Ulizia, M.; Favro, S.; Ferone, D.; Fidotti, E.; Formoso, G.; Francia, G.; Frigato, F.; Furlani, L.; Galuzzo, A.; Gargiulo, P.; Gasperoni, P.; Gazzaruso, C.; Giorgino, F.; Grandi, M.; Grimaldi, F.; Indovina, S.; Lanzi, R.; Legovini, P.; Limone, P.; Liuzzi, A.; Lo Cascio, V.; Lo Coco, R.; Loli, P.; Mantero, F.; Marchetti, M.; Mariotti, S.; Masala, A.; Meringolo, D.; Monachesi, M.; Montini, M.; Moretti, C.; Muggeo, M.; Mulas, G.; Nizzolo, M.; Oleandri, S.; Orio, F.; Orlandi, F.; Pacini, F.; Palermo, M.; Pancotti, D.; Paoletta, A.; Papini, E.; Parillo, M.; Parisi, G.; Pasquali, R.; Pavoncello, S.; Perego, M. R.; Peri, A.; Peri, D.; Piantoni, L.; Raffa, M.; Raggiunti, B.; Resmini, E.; Rizzi, G.; Rosatello, A.; Rosato, F.; Savino, L.; Scaroni, C.; Sinisi, A.; Stefani, I.; Tamburrano, G.; Tanda, M.; Terzolo, M.; Testa, I.; Testa, R.; Testori, G.; Toscano, Vincenzo; Tota, N.; Travaglini, P.; Vailati, A.; Valcavi, R.; Ventre, I.; Vincenzi, W.; Vitale, G.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 31:8(2008), pp. 731-738.
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) study
P. Gargiulo;TOSCANO, Vincenzo;
2008
Abstract
Background: During the course of acromegaly, cardiovascular, respiratory, and metabolic co-morbidities contribute to enhanced mortality. In 2002, the Pituitary Society and the European Neuroendocrine Association sponsored a Consensus Workshop in Versailles during which guidelines for diagnosis and treatment of co-morbidities in acromegaly were defined. However, as for other guidelines previously issued in the field, no data are available on their clinical application. Aim: The aim of this work coordinated by the Italian Study group on co-morbidities evaluation and treatment in acromegaly (COM.E.T.A.) was to assess, on a national basis, the application in the clinical practice of the Versailles criteria for diagnosis and treatment of cardiovascular comorbities in acromegaly. Materials and methods: In January 2007 an ad hoc designed questionnaire was sent by mail to 130 endocrine Centers in Italy. Results: The guidelines have been generally well perceived and translated in clinical practice. Specifically: 1) echocardiography is considered the mainstay for the diagnosis and follow-up; 2) ambulatory blood pressure monitoring and blood lipid assessment are performed in most hypertensive patients; 3) most endocrinologists directly manage hypertension and are aware of the uncertainty of the effect of the control of the disease on blood pressure levels; 4) ACE inhibitors and angiotensin receptors blockers are first-choice anti-hypertensive treatment; 5) approximately half of the centers consider somatostatin analogues of paramount relevance for biochemical control of disease; 6) awareness that left ventricular hypertrophy and heart failure are the most relevant cardiovascular complications is high although the impact of ischemic, arrhythmic, and valvular complications on prognosis is less well perceived. Conclusion: The results of the present survey suggest that previuosly issued guidelines are generally carefully followed in the clinical practice. On the other side, a certain lack of awareness of emerging aspects of the cardiovascular comorbities of acromegaly confirms the necessity of periodically updating the guidelines based on the availability of new clinical information. ©2008, Editrice Kurtis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
